Head to head
Fisetin against Navitoclax
The senolytic anyone can buy against the senolytic nobody should take. Their mechanisms overlap on the BCL-2 family, which is also the reason navitoclax destroys platelets, and fisetin's own lifespan claim failed to replicate in the programme built to test such claims.
Column A
FisetinFisetin (senolytic flavonoid)
A plant flavonoid and leading natural senolytic. One mouse study reported extended lifespan; the multi-site programme built to replicate such results found no effect.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Side by side, on the facts we can check
| Attribute | Fisetin | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Sold as a supplement; in clinical trials for aging | Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov. |
| Half-life | ~1-3 hours | Not reported |
| Molecular weight | 286.2 Da | Not reported |
| Mechanism | Selectively triggers death of senescent cells, reducing the inflammatory signals they release. | Established in human cells and in mice: navitoclax is a BH3 mimetic that occupies the binding groove of BCL-2, BCL-xL and BCL-w, freeing pro-apoptotic BAX and BAK and triggering apoptosis in cells that depend on those proteins. In mice, that dependency is what makes senescent cells selectively vulnerable. In humans, the same dependency in platelets produces thrombocytopenia, verified in the oncology dose-escalation data. The senolytic selectivity demonstrated in mice has never been demonstrated in a person. |
| Human studies cited | 1 | 4 |
| Legal status, US | Sold as a dietary supplement | Investigational, not approved |
Frequently asked questions
What is the difference between Fisetin and Navitoclax?
Fisetin: A plant flavonoid and leading natural senolytic. One mouse study reported extended lifespan; the multi-site programme built to replicate such results found no effect. Navitoclax: The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Which has stronger research evidence, Fisetin or Navitoclax?
This database does not grade compounds. It counts what was run in people: 1 of the 3 studies cited on the Fisetin profile were human work, against 4 of 7 for Navitoclax. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Fisetin and Navitoclax FDA-approved?
Fisetin: Sold as a supplement; in clinical trials for aging. Navitoclax: Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov..
Related posts
Blog articles that cover Fisetin or Navitoclax, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 8, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.